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Xanthones are a group of oxygenated heterocyclic compounds with anticancer properties, but poor aqueous solubility and low
oral bioavailability hinder their therapeutic application. This study sought to prepare a xanthones extract (81% 𝛼-mangostin
and 16% 𝛾-mangostin) in polymeric nanoparticles and to investigate its intracellular delivery and cytotoxicity toward colon
cancer cells. The nanoparticles were prepared in Eudragit RL100 and Eudragit RS100 by the nanoprecipitation method at drug
loading and entrapment efficiency of 20% and >95%, respectively. Freeze-drying of bulk nanoparticle solutions, using glucose
or sucrose as cryoprotectants, allowed the collection of nanoparticles at >95% yield. Solubility of the xanthones extract was
improved from 0.1 𝜇g/mL to 1250𝜇g/mL. Transmission electron microscopy (TEM) and dynamic light scattering (DLS) of the
freeze-dried final formulation showed the presence of cationic round nanoparticles, with particle size in the range of 32–130 nm.
Scanning electron microscopy (SEM) showed the presence of nanospheres, and Fourier transform infrared (FTIR) spectroscopy
indicated intermolecular interaction of xanthones with Eudragit polymers. Cellular uptake of nanoparticles was mediated via
endocytosis and indicated intracellular delivery of xanthones associated with potent cytotoxicity (median inhibitory concentration
26.3 ± 0.22 𝜇g/mL). Presented results suggest that cationic nanoparticles of xanthones may provide a novel oral drug delivery sys-
tem for chemoprevention or treatment of intestinal and colon tumors.
1. Introduction
Xanthones fromGarciniamangostanaL. fruit rinds have been
reported as potential anti-colon cancer candidates [1]. More
than 50 xanthones have been isolated from the fruit rind [2];
the most studied and abundant compounds are 𝛼-mangostin
(1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-9H-
xanthen-9-one) and 𝛾-mangostin (1,3,6,7-tetrahydroxy-2,8-
bis(3-methylbut-2-enyl)xanthen-9-one) [2, 3] (Figure 1). The
compounds are gaining remarkable interest due to their
significant pharmacological effects such as anticancer
[1, 4–7], anti-inflammatory [8, 9], antimicrobial [10, 11],
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Figure 1: Chemical structure of 𝛼- and 𝛾-mangostins (the main components of the xanthones extract) and the Eudragit RL100 and Eudragit
RS100 polymers.
cardioprotective [12], analgesic [13], and antioxidant effects
[14], as well as enhancement of the immune system [15, 16].
In a previous study conducted in our lab, a xanthones
extract prepared from G. mangostana fruit rinds showed
potent in vitro anti-colon cancer activity equivalent to that
of pure 𝛼-mangostin. The anticancer effect of the extract
was mediated via upregulation of the p53, Myc/Max, and
MAPK/ERK cell signaling pathways [17]. Therefore, this
extract (containing 81% 𝛼-mangostin and 16% 𝛾-mangostin)
may provide a cost-effective alternative to the pure com-
pound in the treatment or chemoprevention of colon cancer.
However, the extract and 𝛼-mangostin suffer poor aqueous
solubility and very low oral bioavailability [18]; these can
be major obstacles toward the therapeutic application of G.
mangostana xanthones.
Polymeric nanoparticles are versatile drug delivery sys-
tems that can improve aqueous solubility and overcome the
physiologic barriers to deliver drugs to their site of action.
This study utilized the time-dependent colon targeting
approach by using the cationic polymers Eudragit RL100 (E-
RL100) and Eudragit RS100 (E-RS100). These are copolymers
of ethyl acrylate, methyl methacrylate, and a low content of
a methacrylic acid ester with quaternary ammonium groups
(Figure 1). The ammonium groups are present as salts and
make the polymers permeable.
Due to their low chemical reactivity and low toxicity,
these polymers have beenwidely used in tablet coating to pro-
vide time-dependent colonic targeting and recently reported
in preparation of mucoadhesive and time-dependent release
nanoparticles (NPs) [19]. Their cationic charge and mucoad-
hesive properties [20, 21] provide direct contact of the NPs
with the gastrointestinal tract (GIT) mucosa, which may
increase the likelihood of cellular uptake by endocytosis and
increase the transit time of NPs in the GIT, leading to
improved therapeutic efficacy.The endocytotic uptake of NPs
has been extensively reported as a novel approach to over-
come multidrug resistance, the major cause of drug failure
in cancer chemotherapy [22]. This study reports preparation,
characterization, and intracellular delivery of cationic NPs of
G. mangostana xanthones in E-RL100/E-RS100 polymers, as
a time-dependent and intracellular drug delivery system.
The NPs were prepared by nanoprecipitation at vari-
ous drug loading, polymer concentration, E-RL100 : E-RS100
ratio, and surfactants. The NPs were collected by freeze-
drying of the bulk NP solutions, the drug content was deter-
mined by UV spectrophotometry, and the particle size and
zeta potential were determined by dynamic light scattering
(DLS). NPs morphology was studied by TEM and SEM,
the interaction between the polymers and the extract was
investigated by FTIR, and the intracellular delivery of NPs
was investigated on human colorectal carcinoma cell line
HCT 116 by fluorescent microscopy.
2. Materials and Methods
2.1. Materials. E-RS100 and E-RL100 were obtained as a gift
from Evonik Degussa (International Business Park, Nordic
European Centre, Singapore). The reference compounds
were purchased from ChromaDex (Irvine, California). Pen-
icillin/streptomycin solution, dimethyl sulfoxide (DMSO),
phosphate buffered saline (PBS), tween 80, tween 20, poly-
vinyl alcohol-72000 Dalton (PVA-72000Da), glucose, glycine,
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sucrose, dextran 40000Da, glycerol, mannitol, 2,3-bis(2-
methoxy-4-nitro-5-sulfophenyl)-2h-tetrazolium-5-carboxa-
nilide inner salt (XTT), and phenazine methosulfate (PMS)
were purchased from Sigma-Aldrich (Kuala Lumpur, Malay-
sia). Analytical grade acetone and high-performance liquid
chromatography (HPLC) grade acetonitrile were obtained
fromAvantor PerformanceMaterials (Petaling Jaya, Selangor,
Malaysia). HCT 116 cell line was purchased from the Amer-
ican Type Culture Collection (ATCC, Manassas, Virginia).
RPMI 1640 cell culture medium (without phenol red) and
fetal bovine serum (FBS) were purchased from Bio-Diag-
nostics (Petaling Jaya, Selangor, Malaysia).
2.2. Preparation and Standardization of the Xanthones Extract.
The xanthones extract was obtained at 5% yield (wt/wt) from
G. mangostana fruit rinds and was standardized by Liquid
Chromatography-Mass Spectrometry (LC-MS) [17]. Briefly,
the fruit rind powder was macerated in toluene at 60∘C for
48 h, filtered, concentrated, and crystallized at 2–8∘C for 24 h
to give a yellow precipitate. The precipitate was collected and
further dried at 50∘C for 24 h.
The concentration of total xanthones was determined
by Ultraviolet (UV) spectrophotometry. In brief, the opti-
cal density (OD) of a methanolic solution of the extract
(50𝜇g/mL) wasmeasured at 243.4 nm, and the concentration
of total xanthoneswas then determined by applying the linear
regression equation of 𝛼-mangostin reference compound.
The result is presented as % (wt/wt) as the following:
Total xanthones % (wt/wt)
= (
Calculated xanthones concentration
Theoretical xanthones concentration
) × 100.
(1)
Dionex-Ultimate 3000 HPLC system, coupled with a
MicroTOF-Qmass spectrometer, was used in theMS analysis
of the extract. Separation was carried out on a reverse phase
Nucleosil C18 column (5 𝜇m, 4.6 × 250mm) at 30∘C with a
mobile phase consisting of 95% acetonitrile and 5% of 0.1%
H
3
PO
4
in water, for 10min at 0.5mL/min. The spectral data
were collected at 244 nm, and mass scanning was set in the
range of 50–1000 m/z, in the negative ion mode with the
nebulizer set to 3.0 bars and heated to 150∘C. The capillary
voltagewas set at 3000Vusing a nitrogen dry gas at a flow rate
of 8.0 L/min. The end plate offset was maintained at −500V.
2.3. Determination of Aqueous Solubility of the Xanthones
Extract. Aqueous solubility of the xanthones extract was
determined by the shake flask method [23]. The experiment
was carried out at 37∘C in PBS at pH 7.4, with various con-
centrations (wt/v) of tween 80 (0.0, 0.1, 0.5, 1.0, and 2.0%).
Briefly, 5mg of pulverized extract was added to 25mL glass
vials containing 10mL buffered solutions. The samples were
then mixed for 24 h in a shaker incubator at 200 rpm. Subse-
quently, the samples were filtered through 0.2𝜇m syringe fil-
ters, and the concentration of total xanthoneswas determined
by UV spectrophotometry as mentioned above.
2.4. Preparation of the NPs. NPs of the xanthones extract were
prepared in E-RL100 and E-RS100 by the nanoprecipitation
method developed by Fessi et al. [24]. The polymers and the
extract were dissolved separately in acetone at room temper-
ature (RT). The organic phase was then prepared by mixing
both solutions on amagnetic stirrer for 30min. Subsequently,
the organic phase was added slowly to the aqueous phase
(double distilled water (dd.H
2
O)with or without surfactants)
by means of syringe attached to a 27G needle, inserted
directly into the aqueous phase while mixing at 700 rpm.
Acetone was then evaporated at 50∘C on a magnetic stirrer at
600 rpm for 4 h, and the agglomeration (if any) was removed
by vacuum-filtration through a 0.8 𝜇mmembrane filter.
2.5. Determination of the Entrapment Efficiency. The solvent
was removed as described above and the precipitated free
drug and the agglomerated NPs (if any) were removed by
vacuum-filtration through a 0.8 𝜇m membrane filter giving
transparentNP solutions.The entrapment efficiencywas then
determined by UV spectrophotometry as the following: the
transparent NP solutions were diluted in methanol, and the
OD was recorded at 243.4 nm. The xanthones concentration
was determined as mentioned above, and the entrapment
efficiency was then calculated by applying the following
formula:
% Entrapment efficiency
= (
Measured xanthones concentration
Theoretical xanthones concentration
) × 100.
(2)
2.6. Freeze-Drying of BulkNPs Solutions. Theeffect of various
surfactants and cryoprotectants was evaluated on the freeze-
drying process. Ten milliliters of the bulk NP solutions was
frozen in 25mL glass vials, with or without cryoprotectants,
at −18∘C for 12 h. The solid solutions were then freeze-dried
under vacuum at −50∘C for 48 h using Labconco FreeZone 6
drying system (Labconco, Kansas City, Missouri) and further
dried at 50∘C for 5 h.
2.7. Evaluation of Freeze-Drying Efficiency. The efficiency of
freeze-drying process was determined by studying the cake
morphology, the ease of reconstitution, and aqueous solubil-
ity of the freeze-dried NPs.
The freeze-dried cakes were identified as intact with the
same volume (IS), collapsed (C), or partially collapsed (PC).
The freeze-dried cakes were then reconstituted in the
same volume of water andwere given a score as the following:
reconstituted immediately (++++), reconstituted after several
manual inversions for 1min (+++), reconstituted after vortex
for 1min (++), reconstituted after sonication (+), and not
reconstituted after sonication (0) [25].
Concentration of the soluble fraction of the entrapped
xanthones (aqueous solubility) in the reconstituted NPs was
determined as the following: the reconstituted NP solutions
were centrifuged at 2300×g for 5min using Tomy MX-305
centrifuge (Tomy Seiko Co. Ltd., Tokyo, Japan), the super-
natant was filtered through a 0.2 𝜇m syringe filter, and the
concentration of total xanthones in the filtrate was measured
by UV spectrophotometry as mentioned in the previous
sections.
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2.8. Determination of the Percentage Yield. The bulk NPs
solutions were freeze-dried as mentioned above. The vials
were weighed accurately, and the weight of NPs was deter-
mined from the difference between the empty and loaded
vials. The percentage yield was then calculated using the
following formula:
% Yield = (
𝑊
𝑅
𝑊
𝑇
) × 100, (3)
where𝑊
𝑅
is the recorded weight of freeze-dried NPs and𝑊
𝑇
is the theoretical yield of polymers, drug, and surfactant.
2.9. Measurement of the Particle Size and Zeta Potential.
Particle size, polydispersity index (PDI), and zeta potential
(𝜁) were determined by DSL using a Zetasizer nano zs
(Malvern Instruments Ltd., Malvern, Worcestershire, UK).
The samples were filtered through a 0.2 𝜇m syringe filter, and
the measurements were carried out in triplicate.
To examine the effect of pH on particle size and zeta
potential, the freeze-dried formulation was reconstituted in
dd.water and then diluted in phosphate buffered saline (PBS)
at various pH values (5.5, 6.8, and 7.4); the samples were
mixed well and incubated in a water bath at 37∘C for 18 hours.
The agglomeration (if any) was removed by filtration through
a membrane filter (0.8 𝜇m).
2.10. Transmission and Scanning Electron Microscopy. One
drop of the NP solution was deposited on a 400-mesh copper
grid coated with 5 nm layer of carbon and air-dried at RT.
The samples were then studied at different magnifications in
a Philips CM12 TEM used to study the samples. Morphology
and dispersity of freeze-dried NPs were examined by SEM.
The samples were freeze-dried, with or without cryoprotec-
tant, coated with 3–6 nm Platinum by sputter deposition at
−120∘C, and analyzed in a LEO Supra 50 VP field emission of
Carl Zeiss SEM.
2.11. Fourier Transform Infrared Spectroscopy. The interaction
between the E-RL100/E-RS100 and the xanthones extract
was investigated using attenuated total reflectance FTIR
(ATR/FTIR) spectroscopy as measured with a Perkin Elmer
Spectrum 400 spectrometer. The spectra of nonformulated
xanthones, empty NPs, physical mixtures (PMs), and loaded
NPs were recorded in the range of 4000–650 cm−1 (𝑛 = 3).
To ensure the homogenous PMs formation, the components
were ground to a fine powder and thoroughly mixed using a
mortar and pestle.
2.12. Evaluation of the In Vitro Release. In vitro release studies
were performed under sink conditions (1 : 12) by reverse
dialysis method at 37∘C with continuous stirring at 100 rpm.
Five milliliters of NPs solution (equivalent to 6.2mg of xan-
thones extract) was diluted in 500mL release medium (0.5%
tween 80 in PBS). Sixteen dialysis bags (molecular weight
cut-off 8200Da) were loaded with 2mL release medium,
hermetically sealed, and kept in the donor compartment.The
drug release was studied at different pH values in sequence,
namely, 1.6 (2 h), 5.5 (1 h), 6.8 (3 h), and 7.5 (42 h) [26]; the pH
was adjusted by adding 5M NaOH. One bag was removed at
0, 0.5, 1, 2, 3, 4, 5, 6, 9, 12, 18, 24, 30, 36, 42, and 48 h. The
bag content was filtered through a 0.45-𝜇m syringe filter and
was analyzed by HPLC as follows: Dionex-Ultimate 3000
HPLC system (Dionex, Sunnyvale, California) was used.
Separation was carried out on a reverse phase Nucleosil C18
column (5 𝜇m, 4.6 × 250mm) (Macherey Nagel, Bethlehem,
Pennsylvania) at 30∘C with a mobile phase consisting of 95%
acetonitrile and 5% of 0.1% H
3
PO
4
in water, for 10min at
1.0mL/min. The spectral data were collected at 244 nm. The
experiment was repeated 3 times and the results are presented
as average percentage of cumulative release ± SD.
2.13. Evaluation of the Intracellular Delivery of NPs. The
intracellular delivery of NPs was investigated on HCT 116 cell
line as an in vitromodel of human colorectal carcinoma [27],
as previously described [28]. Cells were maintained in RPMI
1640 culturemedium (without phenol red) and supplemented
with 10% FBS and 1% penicillin/streptomycin. Seventy to
eighty percent of confluent cultures were treated with the
NPs at 20𝜇g/mL for 6 h. Subsequently, the cells were washed
extensively with PBS, fixed in 4% paraformaldehyde, and
visualized immediately at 96xmagnification ofOlympus IX71
inverted fluorescent microscope (Olympus, Shinjuku, Tokyo,
Japan), using the blue filter and maintaining all settings
constant for all treatments.
2.14. Evaluation of Cytotoxic Effect. Cytotoxicity of the non-
formulated xanthones extract, loaded and empty NPs, was
evaluated on HCT 116 cells using XTT assay as previously
described [29]. Cells were seeded in 96-well plate at 1 ×
10
4/well in 100 𝜇L of medium. After overnight incubation,
further 100 𝜇L of fresh medium containing the treatment
compounds was added and incubated for 48 h. Cell viability
was then determined as follows: 20 𝜇L of a mixture of XTT
(1mg/mL) and PMS (10 𝜇g/mL) was added and incubated for
4 h. Later, OD was measured at 450 nm usingThermo Fisher
Scientific microplate reader. Cell-free medium was used as a
blank, and cells treated with the vehicle alone (0.5% DMSO)
were used as negative control, and both were processed in the
same manner as the treated cells. Percentage inhibition was
then calculated using the following formula:
% inhibition = (1 −
(ODsamples −ODblank)
(ODcontrol −ODblank)
) × 100. (4)
The results are presented as average ± SD (𝑛 = 4), and the
median inhibitory concentration (IC
50
) was calculated from
the dose response curves.
2.15. Statistical Analysis. Results are presented as average ±
SD. Statistical analysis was carried out by one-way ANOVA
using SSPS software package 16.0, and difference between
groups was considered significant at 𝑃 < 0.05.
3. Results and Discussion
3.1. Standardization of the Xanthones Extract. Three batches
of the xanthones extract were analyzed by UV spectropho-
tometry and LC-MS. UV 𝜆max was 243.4 nm, and the average
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Table 1: Effect of 3 levels of the polymer and drug loading on particle
size. Nine NP formulations were prepared at 3 levels of drug loading
and polymer concentration using acetone as the solvent and water
without surfactants as antisolvent. The solvent was evaporated and
the particle size was measured by dynamic light scattering. The
results are presented as average particle size ± SD (𝑛 = 3).
Formulation
Polymer
conc.
(mg/mL)
Drug
loading %
(wt/wt)
Particle size
± SD (nm)
Polydispersity
index
F1 25 20 32.0 ± 2.4 0.53
F2 25 33 39.0 ± 0.5 0.43
F3 25 43 52.0 ± 0.4 0.34
F4 50 20 44.0 ± 1.4 0.38
F5 50 33 58.0 ± 0.6 0.32
F6 50 43 70.0 ± 0.6 0.40
F7 100 20 72.0 ± 0.5 0.26
F8 100 33 70.0 ± 0.2 0.32
F9 100 43 70.0 ± 0.4 0.34
xanthones concentration was 98.6 ± 1.3% (wt/wt). LC-MS
analysis showed the presence of 5 compounds: 𝛼-mangostin
(80.8 ± 1.6%), 𝛾-mangostin (15.6 ± 1.6%), garcinone c (1.4 ±
0.1%), 8-deoxygartanin (1.2 ± 0.1%), and 𝛽-mangostin (0.9 ±
0.03%). The results indicate good reproducibility of extrac-
tion and standardization procedures.
3.2. Aqueous Solubility of the Xanthones Extract. In the
absence of tween 80, the aqueous solubility of the extract
was 0.1 ± 0.01 𝜇g/mL, which was improved to 37.0 ± 0.5,
150.0 ± 0.6, 263.0 ± 2.0, and 409.0 ± 3.0 𝜇g/mL, by adding
tween 80 at 0.1, 0.5, 1.0, and 2.0% (wt/v), respectively.
3.3. Effect of Polymer Concentration and Drug Loading on
Particle Size. The polymer was made of 1 : 1 mixture (wt/wt)
of E-RL100 : E-RS100, the aqueous phasewas dd.H
2
Owithout
surfactant, and the effect of 3 levels of the polymer and
drug loading was investigated on particle size. The results
indicate spontaneous formation of NPs upon addition of
the drug/polymer solution to the aqueous phase. At 25 and
50mg/mL of the polymer, the particle size was increased, in
a dose-dependent manner, by increasing the drug loading
(Table 1). However, at 100mg/mL of the polymer, changing
the drug loading has no significant effect on particle size (𝑃 >
0.05), though the particle size was higher than that at 25 and
50mg/mL. The data also indicate the presence of surfactants
is not essential for the formation ofNPs in thismethod, which
was also reported by other researchers [30, 31]. After a storage
for few days at RT, crystal growthwas noticed in formulations
prepared at 33% and 43% drug loading and those prepared
at 100mg/mL of the polymer, which indicates instability of
the NPs. Therefore, polymer concentration at 50mg/mL and
drug loading at 20%were selected for further optimization of
the production of NPs.
3.4. Optimization of E-RL100 : E-RS100 Ratio. Polymer con-
centration was fixed at 50mg/mL, the drug loading was
set at 20%, and the aqueous phase was dd.H
2
O without
surfactant.The effect of various E-RL100 : E-RS100 ratios was
investigated on the entrapment efficiency, particle size, PDI,
zeta potential, and the percentage yield (Table 2). There was
no significant effect of the ratio of the two polymers on the
entrapment efficiency (𝑃 = 0.37). On the other hand, the
particle size, zeta potential, and the percentage yield were
significantly affected, with 𝑃 values <0.05. Furthermore, the
particle size was substantially decreased by increasing the E-
RL100 : E-RS100 ratio by ≥3 : 1.
The NPs bulk solutions were then freeze-dried with
1% sucrose as cryoprotectant and were reconstituted in the
same volume of dd.H
2
O. The aqueous solubility and particle
size were significantly affected by changing the ratio of the
two polymers (𝑃 = 0.0) (Table 3). The highest aqueous
solubility and smallest NPs were obtained at 3 : 1 ratio E-
RL100 : E-RS100.Therefore, this ratio was selected for further
optimization in the production of NPs of the xanthones
extract.
3.5. Effect of pH on Particle Size and Zeta Potential. The par-
ticle size and the zeta potential of nanoparticles in the freeze-
dried final formulation were found to increase upon decreas-
ing the pH of the medium due to increased hydronium ions
concentrations which is accompanied by a decrease in the
polydispersity index (Table 4).
3.6. Effect of Surfactants on Particle Size and Entrapment
Efficiency. In this study, the polymer concentration was set
at 50mg/mL at 3 : 1 ratio E-RL100 : E-RS100 and 20% drug
loading.The effect of 2 levels of 3 surfactants was investigated
on particle size and entrapment efficiency.The results showed
that entrapment efficiency was not affected by the presence
of the surfactants, and it was 100% in all formulations. On
the other hand, the surfactants have significant effect on
the particle size (𝑃 = 0.0), where the smallest NPs were
obtained at 0.1% tween 80 and 0.05% tween 20 (Table 5).
It might be assumed that the high entrapment efficiency is
due to the presence of free compounds in the NPs solution.
This presumption was excluded as follows: the free xanthones
showed low aqueous solubility (37.0 ± 0.5 𝜇g/mL) at tween 80
concentration of 0.1%. In the NPs solution, at the same tween
80 concentration, the concentration of soluble xanthones was
found to be 1250.0 ± 4.0 𝜇g/mL. If there are unentrapped
xanthones in the NPs solution, their concentration should
not exceed 37.0 ± 0.5 𝜇g/mL, and any xanthones beyond
this concentration tend to precipitate and can be removed
by filtration. Therefore, we can conclude that the high
entrapment efficiency of xanthones in the Eudragit NPs is not
due to the presence of free xanthones in the solution, but due
to entrapment of xanthones in the NPs leading to substantial
improvement in their aqueous solubility.
3.7. Optimization of Freeze-Drying Process. The NPs in this
study were produced at polymer concentration of 50mg/mL,
3 : 1 E-RL100 : E-RS100, 20% drug loading, and with or with-
out surfactants. The bulk NP solutions of 7 formulations
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Table 2: Effect of the E-RL100 : E-RS100 ratio on NPs characteristics. NPs were prepared without surfactants at 20% drug loading and various
E-RL100 : E-RS100 ratios. The solvent was evaporated, the free drug was removed by filtration, and the entrapment efficiency, particle size,
polydispersity index, zeta potential, and percentage yield were determined. The results are depicted as average ± SD (𝑛 = 3).
Formulation E-RL100 : E-RS100 (wt/wt) E. efficiency (%) P. size (nm) Polydispersity index Z. potential (mV) Yield (%)
F1 0 : 1 96.0 ± 7.0 72.0 ± 0.4 0.21 ± 0.01 34.0 ± 0.7 86 ± 0.1
F2 1 : 3 96.0 ± 6.0 77.0 ± 0.6 0.19 ± 0.01 32.0 ± 0.9 92 ± 0.1
F3 1 : 1 101.0 ± 1.0 65.0 ± 0.4 0.20 ± 0.00 34.0 ± 2.9 98 ± 0.2
F4 3 : 1 94.0 ± 0.1 45.0 ± 0.3 0.19 ± 0.01 31.0 ± 1.0 99 ± 0.3
F5 1 : 0 98.0 ± 1.0 46.0 ± 0.1 0.21 ± 0.00 30.0 ± 1.4 91 ± 0.3
Table 3: Effect of E-RL100 : E-RS100 ratio on the aqueous solubility and particle size of freeze-dried NPs. The NPs (20% drug loading) bulk
solutions were freeze-dried with 1% (wt/v) sucrose and the resulting cakes were reconstituted in the same volume of water, vortexed for 1min,
and sonicated for 10min, and the insoluble material was removed by centrifugation. The drug content in the supernatant was measured by
UV spectrophotometry and the particle size was measured by photon correlation spectroscopy.The results are presented as average solubility
(𝜇g/mL) and average particle size (nm) (𝑛 = 3).
Formulation E-RL100 : E-RS100 (wt/wt) Aqueous solubility (𝜇g/mL) Particle size (nm) Polydispersity index
F1 0 : 1 340.0 ± 3.0 130.0 ± 0.2 0.43 ± 0.12
F2 1 : 3 917.0 ± 22.0 83.0 ± 0.7 0.21 ± 0.01
F3 1 : 1 972.0 ± 12.0 72.0 ± 0.4 0.25 ± 0.01
F4 3 : 1 968.0 ± 2.0 52.0 ± 0.2 0.24 ± 0.00
F5 1 : 0 591.0 ± 6.0 84.0 ± 0.5 0.20 ± 0.01
Table 4: Effect of pH on particle size and zeta potential. The freeze-
dried final formulation was reconstituted in dd.water and then
diluted in phosphate buffered saline at various pH values (5.5, 6.8,
and 7.4); the samples were mixed well and incubated in water bath
at 37∘C for 18 h.The agglomeration (if any) was removed by filtration
through membrane filter (0.8 𝜇m). The results are presented as
average ± SD (𝑛 = 3).
pH Size (nm) Zeta potential (mV) PDI
7.4 42.0 ± 0.3 0.8 ± 2.2 0.60 ± 0.01
6.8 73.0 ± 0.6 3.0 ± 2.1 0.30 ± 0.01
5.5 85.0 ± 0.4 4.2 ± 0.4 0.17 ± 0.01
were freeze-dried with 6 cryoprotectants, and a formulation
was freeze-dried without a cryoprotectant for reference.
The cryoprotectants were used at a final concentration of
0.25% (wt/v), and the cryoprotectant(s) with the highest
cryopreservation effect was selected based on the cake
appearance, ease of reconstitution, and xanthones aqueous
solubility.
Based on the cake appearance, the freeze-dried NPs were
classified into 3 categories: intact with same volume (IS),
partially collapsed (PC), or collapsed (C) (Table 6).
The freeze-dried NPs were then reconstituted in the same
volume of dd.water and were given a score as described in the
materials and methods. The results are displayed in Table 7.
The aqueous solubility of freeze-dried NPs was then
utilized in the selection of cryoprotectants. The highest
solubility was achieved in NPs freeze-dried with glycerol,
glucose, and sucrose, particularly in the formulation prepared
with 0.1% tween 80 (Table 8). Mannitol, glycine, and dextran
produced intact cakes, but with low aqueous solubility,
which suggests them to be bulking reagents. The results also
indicate that freeze-drying without a cryoprotectant resulted
in irreversible agglomeration of the NPs leading to very low
reconstitution. Though the presence of surfactants is not
essential for the formation of NPs in this method, the NPs
prepared without surfactants showed very low reconstitution
compared to those prepared with 0.1% tween 80, which
indicates the crucial role of tween 80 in the success of the
freeze-drying process.
3.8. Optimization of Glucose, Sucrose, and Glycerol Con-
centration. The NPs prepared with 0.1% tween 80 were
chosen, and the aqueous solubility was selected as themarker
for optimizing the cryoprotectant concentration. Glucose,
glycerol, and sucrose were used in the concentration range
of 0.125–1.0% (wt/v). The results showed a dose response
effect on aqueous solubility and hence on reconstitution of
freeze-dried NPs (Table 9). The freeze-dried formulation
prepared with glycerol produced collapsed cakes but totally
reconstituted after sonication.On the other hand, intact cakes
were obtained in both glucose and sucrose, and the NPs
were reconstituted either immediately (++++) or after several
manual inversions (+++). The formulation with successful
freeze-drying produced clear solutions after reconstitution in
water, whereas those that made the freeze-drying process fail
did not redisperse and showed obvious agglomeration of NPs
(Figure 2). Collectively, the best freeze-drying results were
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Table 5: Effect of surfactants on entrapment efficiency and particle size.TheNPs were prepared at 20% drug loading with various surfactants,
and the entrapment efficiency and particle size were measured by UV spectrophotometry and photon correlation spectroscopy, respectively.
The results are presented as average ± SD (𝑛 = 3).
Formulation Surfactant Surfactant conc. %
(wt/v)
Entrapment efficiency
(%)
Particle size (nm) Polydispersity
index
F4-A Tween 80 0.10 100.0 ± 0.3 39.0 ± 0.1 0.24 ± 0.01
F4-B Tween 80 0.05 100.0 ± 0.3 48.0 ± 0.2 0.20 ± 0.01
F4-C Tween 20 0.10 100.0 ± 0.5 44.0 ± 0.1 0.22 ± 0.01
F4-D Tween 20 0.05 100.0 ± 0.7 39.0 ± 0.1 0.20 ± 0.01
F4-E PVA 0.10 100.0 ± 0.4 55.0 ± 0.2 0.21 ± 0.01
F4-F PVA 0.05 100.0 ± 0.3 47.0 ± 0.1 0.21 ± 0.01
F4-G None 0.00 100.0 ± 0.1 46.0 ± 0.3 0.19 ± 0.01
Table 6: Cake appearance of the freeze-dried NPs. The bulk NPs
solutions were freeze-dried with various cryoprotectants at 0.25%
(wt/v). The freeze-dried cakes were then identified as the following:
intact with the same volume (IS), collapsed (C), and partially
collapsed (PC).
Cryoprotectants
Formulations
Cake appearance
Tween 80 Tween 20 PVA None
0.1% 0.05% 0.1% 0.05% 0.1% 0.05%
Sucrose IS PC IS IS IS IS IS
Glucose PC PC IS PC IS IS IS
Mannitol PC IS IS IS IS IS IS
Glycine PC IS PC IS IS IS IS
Glycerol C C C C PC PC PC
Dextran 40000 IS IS IS IS IS IS IS
None PC PC PC IS IS IS PC
Table 7: Ease of reconstitution of the freeze-dried NPs. The freeze-
dried cakes were reconstituted in the same volume of water and
were given a score as the following: reconstituted immediately
(++++), reconstituted after several manual inversions for 1min
(+++), reconstituted after vortex for 1min (++), reconstituted after
sonication (+), and not reconstituted after sonication (0).
Cryoprotectant
Formulations
Ease of reconstitution
Tween 80 Tween 20 PVA None
0.1% 0.05% 0.1% 0.05% 0.1% 0.05%
Sucrose ++ + ++ ++ + + 0
Glucose ++ ++ ++ +++ +++ +++ 0
Mannitol 0 0 0 0 0 0 0
Glycine 0 0 0 0 0 0 0
Glycerol +++ ++ + +++ +++ +++ 0
Dextran 40000 0 0 0 0 0 0 0
None 0 0 0 0 0 0 0
Table 8: Aqueous solubility of freeze-dried NPs. The freeze-dried
cakes were reconstituted in the same volume of water, vortexed for
1min, and sonicated for 10min, the insoluble material was removed
by centrifugation, and the concentration of the total xanthones in the
supernatant was measured by UV spectrophotometry. The results
are presented as average solubility (𝜇g/mL).
Cryoprotectants
Formulations
Aqueous solubility (𝜇g/mL)
Tween 80 Tween 20 PVA None
0.1% 0.05% 0.1% 0.05% 0.1% 0.05%
Sucrose 714 83 429 46 460 305 144
Glucose 786 566 371 457 198 482 236
Mannitol 92 38 101 25 35 75 12
Glycine 38 22 105 11 54 134 12
Glycerol 1196 964 500 898 771 372 276
Dextran 40000 54 104 309 27 28 148 26
None 50 45 107 12 33 44 9
The Relative Standard Deviation was <0.4% of the values presented in the
table and was not included for simplicity purposes.
Table 9: Cryopreservation effect of glucose, glycerol, and sucrose.
The bulk NPs solutions were freeze-dried with various concentra-
tions of glucose, sucrose, and glycerol. The freeze-dried cakes were
then reconstituted in the same volume of water, vortexed for 1min,
and sonicated for 10min, the insoluble material was removed by
centrifugation, and the concentration of the total xanthones in the
supernatant was measured by UV spectrophotometry. The results
are presented as average solubility (𝜇g/mL).
Cryoprotectant
concentration % (wt/v)
Aqueous solubility (𝜇g/mL)
Glucose Sucrose Glycerol
0.125 684.0 ± 1.0 180.0 ± 1.0 805.0 ± 1.0
0.25 1013.0 ± 1.0 545.0 ± 1.0 1118.0 ± 2.3
0.375 1245.0 ± 1.0 1027.0 ± 1.0 1153.0 ± 1.0
0.5 1262.0 ± 1.0 1228.0 ± 1.0 947.0 ± 1.0
0.75 1238.0 ± 1.0 1259.0 ± 1.5 993.0 ± 1.0
1.0 1169.0 ± 1.0 1180.0 ± 5.4 1033.0 ± 1.0
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Figure 2: Appearance of the nanoparticle solutions. The NPs were
prepared at polymer concentration of 50mg/mL, 20% drug loading,
and an aqueous phase of 0.1% tween 80. The NPs solution was
photographed before freeze-drying (a) and after reconstitution of
the freeze-dried NP cakes, without cryoprotectant (b), with 0.5%
glucose (c), with 0.5% sucrose (d), and with 0.5% glycerol (e).
obtained with glucose and sucrose in the concentration range
of 0.25–0.75% (wt/v).
Particle size measurements of the reconstituted NPs
further confirmed the high cryopreservation efficiency of
glucose and sucrose; the data indicate that particle size was
slightly increased from 39 ± 0.1 nm to 43 ± 0.2 nm with 0.5%
glucose and to 52 ± 0.2 nm with 0.5% sucrose. Furthermore,
the percentage yield in these formulations was 100 ± 1.0%.
3.9. Transmission and Scanning Electron Microscopy. TEM
studies showed the presence of round NPs (Figure 3(a)),
and studies in SEM showed the presence of spherical NPs
(Figure 3(b)). The NPs freeze-dried without cryoprotectant
showed irreversible agglomeration of NPs (Figure 3(c)),
which explain their very low reconstitution. On the contrary,
the NPs freeze-dried with glucose showed the presence of
well-dispersed nanospheres embedded within a matrix of the
cryoprotectant. This result indicates that glucose counteracts
the freeze-drying stresses on NPs and hence hampers their
agglomeration, maintains their integrity, and consequently
eases their reconstitution. The SEM study may also give
some insights into the presence of free extract in the NPs
solution; the free compounds tend to crystallize upon freeze-
drying, and the presence of crystals can be detected by
SEM. However, SEM study of freeze-dried NPs showed the
presence of nanospheres embedded within a matrix of the
cryoprotectant and did not show the presence of any crystals.
These results exclude the presence of free compounds in the
NPs solution and further indicate that the high entrapment
efficiency is due to entrapment of the compounds within the
NPs.
3.10. Fourier Transform Infrared Spectroscopy. The inter-
molecular interaction between the drug and polymers com-
monly leads to changes in the FTIR patterns. FTIR pattern
of the nonformulated xanthones, E-RL100/E-RS100 mixture,
loaded NPs, and the PMs of the xanthones and polymers are
displayed in Figure 4. Matching up to FTIR spectrum of the
xanthones extract with the PMs at 20% drug concentration
revealed no distinctive changes indicating that E-RL100/E-
RS100 was not involved in intermolecular interaction with
the xanthones in the PMs. However, the intermolecular
interaction between xanthones and E-RL100/E-RS100 can be
observed in the FTIR spectrum obtained for the loaded NPs
(20% drug loading). The disappearance of the stretching of
xanthones hydroxyl (OH) at 3563, 3416, and 3251 cm−1 and
the redshift in peak position of the polymer’s carbonyl groups
from 1723 to 1728 cm−1 may be attributed to the hydrogen
bonding interaction between xanthones OH groups and the
Eudragit C=O groups in the loadedNPs.The hydrogen bond-
ing between the compounds and the carriers may explain the
high entrapment efficiency of the xanthones in the Eudragit
NPs.
3.11. InVitro Release. Drug releasewas performed under sink
conditions that guarantee solubility of released compounds,
and the molecular weight cut-off of dialysis bags (8200Da)
allows diffusion of 𝛼-mangostin (410.5Da) and 𝛾-mangostin
(396.4Da) down their concentration gradient into the dialy-
sis bags. However, 𝛼- and 𝛾-mangostin could not be detected
in the receiver compartment at the GIT-pH range after
48 h, and hence the cumulative release was 0%. Absence of
drug release can be explained due to the strong interaction
between the drug and the carrier molecules, which can be
attributed to the number of hydrogen bonds between the
xanthones and the polymers (theoretically, 3 hydrogen bonds
in 𝛼-mangostin and 4 in 𝛾-mangostin). Similar results
were reported in our previous study on 𝛼-mangostin/PVP
solid dispersions, where the hydrogen bonding between 𝛼-
mangostin and PVP prevented the release of 𝛼-mangostin in
abiotic system, but the drug was released in the intracellular
compartments of colon cancer cells [28]. The drug release
result may also give insights into the presence of free com-
pounds in the NPs solutions; the free compounds (if any) can
diffuse through the dialysis membrane into the receiver com-
partment. Since the marker compounds were not detected
in the receiver compartment, this excludes the presence of
unentrapped drug in the NPs solution. This result further
supports our conclusion that the high drug entrapment
efficiency is not due to presence of free drug.
3.12. Intracellular Delivery and Cytotoxicity on Colorectal Car-
cinoma Cells. Since there is no drug release in abiotic system,
the drug release was then investigated in a biotic systemmade
of HCT 116 colon cancer cells as a model cell line of colon
cancer. The fluorescent properties of the xanthones extract
(excitation and emission wavelengths at 425 and 480 nm)
were employed to investigate the cellular uptake of the NPs
[28]. Cellular uptake of the cationic NPs was apparent after
6 h of treatment as evident by the presence of blue to green
fluorescence in the cytoplasm of treated cells. On the other
hand, untreated cells did not show any fluorescence and could
hardly be seen (Figure 5). This result suggests that cellular
uptake of the xanthones-loaded NPs may be mediated via
endocytosis, which is facilitated by electrostatic interaction
between the cationicNPs and anionic cytoplasmicmembrane
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Figure 3: TEM and SEM micrographs of nanoparticles. The NPs prepared at 20% drug loading and aqueous phase of 0.1% tween 80 were
studied by TEM (a). The same NP formulation was freeze-dried with and without cryoprotectant and was studied by SEM: micrograph of
freeze-dried NPs with 0.5% glucose (b) and SEMmicrograph of freeze-dried NPs without cryoprotectant (c).
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Figure 4: Fourier transform infrared spectroscopy. Free xanthones
extract (a), empty nanoparticles made of E-RL100 : E-RS100 at 3 : 1
ratio (b), loaded nanoparticles at 20% drug loading (c), and physical
mixtures at 20% drug concentration (d).
of HCT 116 cells. In our previous report, we showed endocy-
totic uptake of 𝛼-mangostin/PVP nanomicelles by HCT 116
colorectal carcinoma cells [28]. Other studies also reported
endocytotic uptake of NPs in HCT 116 cells and other cancer
cell lines [32, 33].
The cytotoxic effect was then investigated, which gave
indirect insights into the intracellular drug release. Firstly,
the morphology of cells was studied using the cytoplasmic
shrinkage and loss of attachment as apoptotic markers. The
results showed rapid changes, within <6 h, in cells treated
with the free extract. On the other hand, cells treated with the
loadedNPs required>24 h to start showing the same changes.
These results indicate delayed onset of cytotoxicity of the
NPs, most likely due to the slow drug release. Secondly, the
cytotoxic effect was measured quantitatively after incubating
the cells for 48 h with the loaded and empty NPs. The results
indicate the empty NPs (prepared under the same conditions
but without the drug) were not cytotoxic to HCT 116 cells.
On the contrary, the free xanthones and xanthones-loaded
NPs caused a dose-dependent killing of cells (Figure 6); IC
50
s
were 6.6 ± 0.30 and 26.3 ± 0.22 𝜇g/mL, respectively. It is
noteworthy to point out that drug release was not detected in
abiotic system under similar conditions of temperature, pH,
and time of the cell culture medium, which, in conjunction
with cellular uptake and cytotoxicity studies, further supports
the conclusion of intracellular drug delivery and release.
Though cytotoxicity of the extract is reduced almost
4-fold in the NPs, the xanthones solubility in the NPs is
improved from 0.1 to 1250𝜇g/mL. In addition, the endocy-
totic uptake of NPs may increase the intracellular delivery
of xanthones and reduce the likelihood of developing drug
resistance by cancer cells.
4. Conclusions
NPs of the xanthones extract were produced at high entrap-
ment efficiency and percentage yield in Eudragit RL100 and
Eudragit RS100 by the nanoprecipitation method. Freeze-
drying of the bulk NPs solutions allowed collection of the
NPs at high percentage yield, which can be used as a
new approach in the collection of NPs. The methodological
simplicity and the reproducibility of procedures make the
upscale production of NPs applicable by this method. The
high entrapment efficiency can be attributed to the hydrogen
bonding interaction between the xanthones and the car-
rier molecules. The substantial enhancement of xanthones
solubility, the endocytotic uptake of the cationic NPs, and
the intracellular delivery of xanthones may provide a novel
drug delivery system for the treatment and prevention of
the gastrointestinal tract tumors, particularly tumors of the
small intestine and the colon. In addition, the sustained
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Figure 5: Cellular uptake of nanoparticles in colorectal carcinoma cells. HCT 116 cells were treated with the loaded NPs, empty NPs, or the
vehicle (0.5% DMSO) for 6 h and photographed at 96x magnification under the blue filter of fluorescent microscopy. Cells treated with the
vehicle (a), empty NPs (b), free extract (c), and loaded NPs (d).
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Figure 6: Dose response cytotoxicity of the loaded nanoparticles.
HCT 116 human colorectal carcinoma cells were treated with loaded
nanoparticles for 48 h, cell viability was determined byXTT test, and
the results are shown as percentage inhibition relative to the negative
control (0.5% DMSO).
intracellular release and the delayed onset of cytotoxicity
may have advantages of reducing the dosing frequency and
hence will be more convenient for patients. The NPs of the
xanthones can be produced for oral delivery such as in cap-
sule form, or in suppositories for topical application via the
rectal route for the treatment of rectal carcinomas. However,
there is a need to study the in vivo anti-colon cancer activity,
pharmacokinetics, and toxicity profile of these NPs.
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